15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Novavax Inc, 4 rate it Buy or better, 1 sit at Hold, and 2 rate it Sell or worse, a hold consensus. Targets range widely, $9.00 to $19.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $12.67 sits 72% above the current $7.37. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.02 next quarter toward $-0.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Hold
Strong Buy00%
Buy457%
Hold114%
Sell229%
Strong Sell00%
Based on 7 analysts giving stock ratings to Novavax Inc.
As of Jul, 4 of 7 firms rate NVAX a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
NVAX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.44 – $0.53 · 7 analysts · -98% YoY
Next period, 7 analysts expect Novavax Inc to earn $-0.02 a share (range $-0.44 – $0.53), versus $-1.25 a year earlier. Full-year consensus is $-0.47, growing to $-0.25 the year after.
REVENUE · NEXT QUARTER
$106.4M
Range $42.6M – $189.7M · 7 analysts · +51% YoY
Revenue is expected to reach $106.4M (range $42.6M – $189.7M), +51.1% year-over-year. Full-year consensus is $410.0M, rising to $258.5M next year.
Top analysts covering Novavax Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVAX.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$18.00+144.4% to target
Overall win rate
53%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Sell
$6.00-18.5% to target
Overall win rate
46%
+ Follow
#3
Sean Lee
HC Wainwright & Co. · Rank #191
Buy
$10.00+35.8% to target
Overall win rate
43%
+ Follow
#4
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #232
Buy
$18.00+144.4% to target
Overall win rate
34%
+ Follow
#5
Thomas Shrader
BTIG
Buy
$19.00+158.0% to target
Coverage
—
+ Follow
NVAX stock forecast FAQ
What is NVAX's average 12-month price target?+
The 3 analysts with a live target average $12.67 for Novavax Inc over the next 12 months, ranging from a $19.00 high to a $9.00 low.
Is NVAX stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 7 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for NVAX?+
The Street-high target is $19.00 (BTIG), and the Street-low is $9.00 (TD Cowen). The average of all 3 active targets is $12.67.
How many Wall Street analysts cover NVAX?+
7 analysts have an active rating on Novavax Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering NVAX?+
Among analysts who currently cover NVAX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $18.00 target.
What is Novavax Inc's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.44 – $0.53) across 7 analysts. Full-year EPS is projected at $-0.47, rising to $-0.25 the following year.
How much revenue is Novavax Inc expected to report next quarter?+
Consensus revenue is $106.4M (range $42.6M – $189.7M). Full-year revenue is projected at $410.0M, growing to $258.5M next year.
Have analysts been upgrading or downgrading NVAX lately?+
As of Jul, 4 of 7 firms rate NVAX a Buy (1 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
